How about Remdesivour vs Ivermectin, and the associated benefits and risks.
The ironic thing about remdesivir is they structured early trials such that they found minimal benefit by restricting it to hospitalized patients. It works as well as Paxlovid early, but by testing it only in hospitalized patients you missed the window of efficacy.
Later on they realized if done early it dramatically lowered hospitalization/severe disease. It would have been worth hospitalizing/sending to infusion centers super high risk patients early in illness to get the infusion much like they did w monoclonal antibodies.
But to think about hydroxychloroquine. Even if it worked it didn't work well, since it was being used a lot in early March 2020. In a world where HCQ was 20% effective we'd still recommend vaccinations just as much and still be recommending paxlovid for high risk people.
Hydroxychloroquine or Ivermectin being effective enough to use wouldn't have changed the calculus on vaccines or antivirals one bit. If either one had been Paxlovid level (90% severe disease reduction) it'd show up in every study you did. That's the only way the drugs would have impacted vaccine makers bottom line.